LumenGuides
AI-Guided Robotic Navigation for Early Lung Cancer Intervention
About
LumenGuides is developing Naviscope, the first AI-guided, single-use robotic navigation platform for bronchoscopy with radiation-free navigation. The technology allows for precise, minimally invasive access to deep lung lesions, enabling earlier detection and treatment of lung cancer.
Key Advantages
- Fiber-optic sensing (FBG) provides real-time 3D airway mapping from inside the lungs.
- No external imaging required (no CT, fluoroscopy, or EMN).
- AI-powered robotic guidance ensures precise, accurate navigation with physician oversight.
- Radiation-free navigation, cost-effective, and faster than traditional methods.
Market Impact
- Current bronchoscopy systems fail to reach ~40% of lung nodules.
- Competing procedures can exceed $20,000 and pose higher risks.
- Naviscope addresses these issues, reducing costs, risk, and exposure while improving outcomes.
- The global bronchoscopy market is projected to reach $17.6B by 2030 (7.4% CAGR).
Progress & Validation
- In-vivo success at Shamir Medical Center (Sept 2025) demonstrating radiation-free navigation.
- US Patent Provisional filed for sensing and robotics integration.
- $1M raised, plus $1.5M IIA grant approved.
- Functional MVP complete with AI-based real-time guidance.
Upcoming Milestones
- Platform and design freeze (V&V).
- First-in-human pilot (30 patients).
- FDA 510(k) submission and expanded pre-clinical studies.
Leadership
Limor Prigan
CEO (Ex-Fujifilm, Avertto, Kornit)
Yaniv Kirma
CTO (Fibernova, acquired by Broncus)
Prof. Doron Kopelman
CMO (Technion, Israeli Surgical Association)
Dan Vigdor
Global Business Development (USA)
Why It Matters
Naviscope represents a meaningful step forward in early lung cancer detection—combining robotics, AI, and fiber-optic sensing into a first-of-its-kind AI-guided navigation system. The company's approach could redefine how clinicians access and treat deep pulmonary nodules.